The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Mechanisms of Hypertension Associated With BAY 43-9006
Abstract
Purpose: BAY 43-9006 (sorafenib) is an inhibitor of Raf kinase, the vascular endothelial growth factor (VEGF) receptor-2, and angiogenesis in tumor xenografts. The current study investigated the incidence, severity, and mechanism of blood pressure (BP) elevation in patients treated with BAY 43-9006. Patients and Methods: Twenty patients received BAY 43-9006 400 mg orally twice daily. BP and heart rate were measured at baseline and then every 3 weeks for 18 weeks. VEGF, catecholamines, endothelin I, urotensin II, renin, and aldosterone were measured at baseline and after 3 weeks of therapy. We assessed vascular stiffness at baseline, after 3 to 6 weeks of therapy, and again after 9 to 10 months of therapy. Results: Fifteen (75%) of 20 patients experienced an increase of ≥ 10 mmHg in systolic BP (SBP), and 12 (60%) of 20 patients experienced an increase of ≥ 20 mmHg in SBP compared with their baseline value, with a mean change of 20.6 mmHg (P < .0001) after 3 weeks of therapy. There were no statistically significant changes in humoral factors, although there was a statistically significant inverse relationship between decreases in catecholamines and increases in SBP, suggesting a secondary response to BP elevation. Measures of vascular stiffness increased significantly during the period of observation. Conclusion: Treatment with BAY 43-9006 is associated with a significant and sustained increase in BP. The lack of significant change in circulating factors suggests that these humoral factors had little role in the increase in BP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Safar, M. E., Levy, B. I., & Struijker-Boudier, H. (2003) · Circulation · doi:10.1161/01.cir.0000069826.36125.b4 · Cited by 1,197
The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis
Wilkinson, I. B., Fuchs, S. A., Jansen, I. M., Spratt, J. C., Murray, G. D., Cockcroft, J. R., & Webb, D. J. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816121-00033 · Cited by 924
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 699
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Amiri, F., Virdis, A., Neves, M. F., Iglarz, M., Seidah, N. G., Touyz, R. M., Reudelhuber, T. L., & Schiffrin, E. L. (2004) · Circulation · doi:10.1161/01.cir.0000144462.08345.b9 · Cited by 346
Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli
Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G., & Cheresh, D. A. (2003) · Science · doi:10.1126/science.1082015 · Cited by 336
Noon, J. P., Walker, B. R., Webb, D. J., Shore, A. C., Holton, D. W., Edwards, H. V., & Watt, G. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119354 · Cited by 331
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Angiogenic growth factors and hypertension
Sane, D. C., Anton, L., & Brosnihan, K. B. (2004) · Angiogenesis · doi:10.1007/s10456-004-2699-3 · Cited by 195
Felmeden, D. C. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)03149-7 · Cited by 155
Siebenhofer, A., Kemp, C., Sutton, A., & Williams, B. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000887 · Cited by 149
The Microcirculation and Hypertension
Struijker-Boudier, H. A. J., & Heijnen, B. F. J. (2012) · Springer eBooks · doi:10.1007/978-88-470-2601-8_17 · Cited by 138
Attenuation of the microcirculation in young patients with high-output borderline hypertension.
Sullivan, J. M., Prewitt, R. L., & Josephs, J. A. (1983) · Hypertension · doi:10.1161/01.hyp.5.6.844 · Cited by 118
Correlation of pathophysiology and pharmacotherapy in primary hypertension
Koch‐Weser, J. (1973) · The American Journal of Cardiology · doi:10.1016/s0002-9149(73)80042-6 · Cited by 115
Stefanadis, C., Karayannacos, P., Boudoulas, H. K., Stratos, C., Vlachopoulos, C., Dontas, I. A., & Toutouzas, P. K. (1993) · Cardiovascular Research · doi:10.1093/cvr/27.6.951 · Cited by 113
Rapid Microvessel Rarefaction With Elevated Salt Intake and Reduced Renal Mass Hypertension in Rats
Hansen‐Smith, F. M., Morris, L. W., Greene, A. S., & Lombard, J. H. (1996) · Circulation Research · doi:10.1161/01.res.79.2.324 · Cited by 106
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584
THOMAS, A., Morgan, B., Drevs, J., Unger, C., Wiedenmann, B., Vanhoefer, U. J., Laurent, D., Dugan, M. H., & Steward, W. P. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70023-2 · Cited by 103
The microcirculation and hypertension
Struijker-Boudier, H. A. J., le Noble, J. L. M. L., Messing, M. W. J., Huijberts, M. S., le Noble, F. A. C., & van Essen, H. (1992) · Journal of Hypertension · doi:10.1097/00004872-199212000-00016 · Cited by 77
Cited by
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630
Self-citation
Metadata
- Authors
- Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend, R. R., & O'Dwyer, P. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-03-20
- Volume
- 24
- Issue
- 9
- Pages
- 1363-1369
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123421036
- Cited by
- 324
- References
- 22
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.